New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
20:25 EDTKO, KO, SCHW, SCHW, NTRS, NTRS, CMA, CMA, WABC, WABC, CNSI, CNSI, PBY, PBY, JNJ, JNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
News For JNJ;KO;SCHW;NTRS;CMA;WABC;CNSI;PBY From The Last 14 Days
Check below for free stories on JNJ;KO;SCHW;NTRS;CMA;WABC;CNSI;PBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
14:04 EDTJNJWorldwide Business Research to hold a conference
Subscribe for More Information
August 29, 2014
16:18 EDTKOCoca-Cola Bottling forms pact with Coca-Cola to expand franchise territory
Coca-Cola Bottling Co. (COKE) announced it has signed a definitive agreement with The Coca-Cola Company (KO) to expand the bottler’s franchise territory to include the Knoxville, TN territory currently served by Coca-Cola Refreshments USA, a wholly-owned subsidiary of The Coca-Cola Company. This agreement represents the second phase of the proposed franchise territory expansion described in the previously-announced Letter of Intent between the company and The Coca-Cola Company. The company expects the transaction to close by the end of October. The company is continuing to work towards a definitive agreement with The Coca-Cola Company for the remainder of the proposed franchise territory expansion described in the previously-announced Letter of Intent, including Cleveland and Cookeville, TN and Louisville, Lexington, Paducah and Pikeville, KY and Evansville, IN. The definitive agreement and other agreements to be entered into at closing will provide the Company the exclusive rights to distribute brands owned by The Coca-Cola Company as well as certain other brands not owned by The Coca-Cola Company that are currently being distributed in the Knoxville territory by CCR. The transaction includes the purchase by the Company of distribution assets and certain working capital items from CCR relating to this territory and the purchase of exclusive rights to distribute certain non-Coca-Cola brands in this territory. The transaction also includes the grant by CCR to the Company of exclusive rights to distribute brands owned by The Coca-Cola Company in this territory under a comprehensive beverage agreement to be entered into at closing. Under such agreement, the Company will make a quarterly sub-bottling payment to CCR on a continuing basis after the closing for the grant of such exclusive rights. The Company will not acquire any production assets from CCR and will, with certain exceptions, purchase finished goods from CCR to service customers in this territory.
August 28, 2014
17:42 EDTJNJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
August 27, 2014
16:05 EDTKOKeurig Green Mountain expands board, appoints José Octavio Reyes Lagunes
Subscribe for More Information
07:45 EDTCMASterne Agee to hold a tour
Texas Bank Tour travels throughout Dallas visiting various banks on August 27-29.
06:58 EDTSCHWMorgan Stanley wins $15M arbitration suit vs. Schwab, Reuters says
A Financial Regulatory Authority arbitration panel in San Francisco ruled that Morgan Stanley (MS) won a $15M arbitration lawsuit against Charles Schwab (SCHW), who accused the bank of unlawfully recruiting brokers from a Schwab San Francisco division that left with confidential data, according to Reuters, citing comments from a Charles Schwab spokesman. The ruling ended a disagreement which had lasted two years. Reference Link
August 26, 2014
06:20 EDTKOCoca-Cola to introduce mid-calorie soda in Mexico, WSJ reports
Subscribe for More Information
August 25, 2014
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 21, 2014
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 18, 2014
13:12 EDTKOAnalysts mixed on Monster Beverage following Coke deal
Analysts had mixed outlooks on energy drink maker Monster Beverage (MNST) in notes to investors earlier today. The analyst comments come after last Thursday night’s announcement that Monster had formed a strategic partnership with Coca-Cola, which included Coca-Cola taking a 16.7% stake in the energy drink maker. BEARISH TAKE: Jefferies analyst Kevin Grundy downgraded Monster Beverage to Hold from Buy, saying that the stock's valuation "looks full" following its rally on Friday. The potential for a strategic deal is no longer a positive catalyst for Monster's stock, as that catalyst largely played out Friday, Grundy believes. Although Coca-Cola is likely to increase its stake in Monster, it will likely take years to do so, the analyst forecast. Additionally, the growth of the global energy drink space has been slowing in recent months, creating risk for Monster, the analyst believes. However, Grundy did raise his price target on the shares to $95 from $80. BULLISH TAKE: The deal is "a big win" for both Monster and Coca-Cola, but Monster will benefit more, analysts at Wells Fargo contended. The deal should significantly increase Monster's opportunity in international markets, according to the firm. Moreover, Wells believes that the market has historically undervalued Monster's international potential, and it estimates that the company's international business is worth about $65 per share. The firm raised its price target range on the stock to $104-$106 from $79-$81 and kept an Outperform rating on the shares. Like Wells Fargo, Credit Suisse expects the deal to accelerate the growth of Monster's international business. Additionally, the firm thinks that Monster could return a significant percentage of the $2.1B it received from Coca-Cola to shareholders, either through share repurchases or a one-time dividend. Credit Suisse increased its price target on Coca-Cola to $98 from $82 and kept an Outperform rating on the shares. PRICE ACTION: In early afternoon trading, Monster dropped 4% to $89.50. On Thursday the stock closed at $71.65.
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
07:41 EDTKOMonster Beverage price target raised to $104-$106 from $79-$81 at Wells Fargo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use